Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand

Mol Pharmacol. 1992 Dec;42(6):1077-82.

Abstract

[3H]L-158,809, a new potent and AT1-selective nonpeptide angiotensin II receptor antagonist, bound saturably and reversibly to rat adrenal membranes. Scatchard and Hill plot analyses indicated a single class of high affinity (Kd = 0.66 nM) binding sites. The relative potencies of various angiotensin II-related peptide and nonpeptide antagonists in displacing [3H]L-158,809 binding correlated with their potencies in displacing the binding of 125I-Sar1,Ile8-angiotensin II to adrenal AT1 receptors. [3H]L-158,809 binding to adrenal membranes was not affected by addition of guanosine-5'-(beta,gamma-imido)triphosphate or various pharmacological agents known to interact with other common peptide and nonpeptide receptor systems. The potencies of angiotensin II receptor agonists, but not antagonists, in inhibiting specific [3H]L-158,809 binding were decreased in the presence of guanosine-5'-(beta,gamma-imido)triphosphate. Specific [3H]L-158,809 binding was also observed in rat liver and kidney. Collectively, the data indicate that [3H]L-158,809 represents a new, potent, nonpeptide, antagonist radioligand suitable for the study of angiotensin II AT1 receptors.

MeSH terms

  • Adrenal Glands / metabolism
  • Angiotensin Receptor Antagonists*
  • Animals
  • Binding, Competitive
  • Biphenyl Compounds / metabolism
  • Guanylyl Imidodiphosphate / metabolism
  • Imidazoles / chemistry
  • Imidazoles / metabolism*
  • Imidazoles / pharmacology
  • Kidney / metabolism
  • Kinetics
  • Liver / metabolism
  • Losartan
  • Molecular Structure
  • Radioligand Assay
  • Rats
  • Tetrazoles / chemistry
  • Tetrazoles / metabolism*
  • Tetrazoles / pharmacology

Substances

  • Angiotensin Receptor Antagonists
  • Biphenyl Compounds
  • Imidazoles
  • Tetrazoles
  • Guanylyl Imidodiphosphate
  • L 158809
  • Losartan